{"hands_on_practices": [{"introduction": "The diagnosis of dermatitis herpetiformis hinges on the accurate execution and interpretation of direct immunofluorescence (DIF) microscopy. However, a negative result in a clinically suspicious case is a common diagnostic dilemma, often stemming from preventable pre-analytical errors. This practice challenges you to apply first principles of immunology and tissue preservation to troubleshoot a failed DIF test, a critical skill for ensuring diagnostic accuracy and avoiding unnecessary delays in patient care. [@problem_id:4433734]", "problem": "A patient with a clinical picture suggestive of dermatitis herpetiformis presents with intensely pruritic grouped papulovesicles on the elbows and buttocks. Serum testing detects high levels of anti–tissue transglutaminase antibodies, and the patient reports improvement with a gluten-free diet. A direct immunofluorescence (DIF) study from a prior biopsy was negative. The laboratory record for the negative DIF indicates that the specimen was placed in normal saline, shipped on ice, arrived after $36$ hours, then slowly frozen in the cryostat without rapid pre-freezing, and sections were stored at $-20^{\\circ}\\text{C}$ for $10$ days with two freeze–thaw cycles prior to staining. You are asked to design a troubleshooting workflow for a repeat DIF to minimize false-negative risk.\n\nUse the following first-principles base to reason about the workflow: antigen–antibody binding depends on preservation of native epitope conformation; protein denaturation and proteolysis rates increase with time and temperature; cross-linking fixatives can mask epitopes and interfere with fluorophore–antibody binding; ice crystal formation during slow freezing disrupts tissue microarchitecture and redistributes immunoreactants; repeated freeze–thaw cycles promote protein aggregation and loss of antigenicity; correct sampling site affects the likelihood of detecting deposited immunoglobulin A (IgA) in dermatitis herpetiformis.\n\nWhich option most appropriately specifies a repeat DIF troubleshooting workflow that addresses specimen transport, freezing artifacts, and prolonged storage to reduce the risk of a false-negative result?\n\nA. Re-biopsy directly from a crusted lesional area, place tissue in formalin to “fix” immunoreactants, ship refrigerated, freeze the block later in a domestic $-20^{\\circ}\\text{C}$ freezer, store sections for $2$ weeks, and stain only for immunoglobulin G.\n\nB. Re-biopsy from perilesional normal-appearing skin adjacent to a fresh lesion on an extensor surface, place tissue immediately in Michel’s transport medium if immediate freezing is not possible, avoid freezing during transport, and upon receipt embed in Optimal Cutting Temperature (OCT) compound and snap-freeze using pre-cooled isopentane in liquid nitrogen to minimize ice crystal formation; cut and stain promptly for immunoglobulin A (IgA) and complement component $3$ (C3), and store any remaining unstained sections at $-80^{\\circ}\\text{C}$ while avoiding repeated freeze–thaw cycles.\n\nC. Sample oral mucosa instead of skin, transport in normal saline at room temperature for $24$ hours, slow-freeze directly in the cryostat without embedding, perform staining for tissue transglutaminase antigen, and keep slides at $4^{\\circ}\\text{C}$ for $1$ month before reading.\n\nD. Use formalin-fixed, paraffin-embedded tissue to perform immunohistochemistry (IHC) for IgA with heat-induced epitope retrieval, incubate slides at $37^{\\circ}\\text{C}$ for $72$ hours before staining, and do not change transport media because fixatives stabilize proteins.", "solution": "The problem statement is scientifically grounded, well-posed, objective, and contains sufficient information to derive a solution. The provided clinical context, laboratory data, procedural details of a failed test, and a set of first principles for immunology and tissue handling constitute a valid basis for a troubleshooting exercise in diagnostic pathology.\n\nThe central task is to design a workflow for a repeat direct immunofluorescence (DIF) test that minimizes the risk of a false-negative result for dermatitis herpetiformis ($DH$). The patient's clinical presentation, high anti-tissue transglutaminase antibodies, and response to a gluten-free diet strongly suggest $DH$. The pathognomonic finding for $DH$ on DIF is granular deposition of immunoglobulin A ($IgA$) in the dermal papillae. The initial negative DIF result is highly suspect, and the provided history of specimen handling reveals multiple critical errors. We will analyze these errors based on the given first principles and then evaluate each proposed workflow.\n\nThe errors in the initial procedure were:\n1.  **Transport Medium:** The specimen was placed in normal saline. The principle \"protein denaturation and proteolysis rates increase with time and temperature\" is relevant here. Normal saline is isotonic but is not a preservative or a fixative; it does not inhibit endogenous proteases present in the tissue. Over a long transport time, these enzymes can degrade the target $IgA$ immunoglobulins.\n2.  **Transport Time and Temperature:** \"$36$ hours\" is a prolonged transport time. Even on ice, enzymatic degradation and protein denaturation can occur, reducing antigenicity.\n3.  **Freezing Method:** The specimen was \"slowly frozen in the cryostat without rapid pre-freezing\". This violates the principle that \"ice crystal formation during slow freezing disrupts tissue microarchitecture and redistributes immunoreactants\". Large ice crystals physically damage the tissue, particularly the delicate dermal-epidermal junction where the $IgA$ deposits are located, potentially destroying the diagnostic pattern or making it uninterpretable.\n4.  **Storage Conditions:** \"sections were stored at $-20^{\\circ}\\text{C}$ for $10$ days with two freeze–thaw cycles\". Two principles are violated here. First, \"repeated freeze–thaw cycles promote protein aggregation and loss of antigenicity\". Each cycle causes damage. Second, storage at $-20^{\\circ}\\text{C}$ is suboptimal for long-term preservation of antigens compared to ultralow temperatures (e.g., $-80^{\\circ}\\text{C}$).\n\nAn ideal repeat workflow must correct all of these deficiencies and also consider the biopsy site, as alluded to by the principle: \"correct sampling site affects the likelihood of detecting deposited immunoglobulin A ($IgA$) in dermatitis herpetiformis\". The ideal site for DIF in $DH$ is clinically normal-appearing perilesional skin, as the inflammatory process within an active vesicle can degrade the $IgA$ deposits.\n\nNow, we will evaluate each option against these principles.\n\n**A. Re-biopsy directly from a crusted lesional area, place tissue in formalin to “fix” immunoreactants, ship refrigerated, freeze the block later in a domestic $-20^{\\circ}\\text{C}$ freezer, store sections for $2$ weeks, and stain only for immunoglobulin G.**\n\n-   **Biopsy Site:** \"a crusted lesional area\" is the incorrect site. Inflammation and enzymatic activity are highest here, leading to degradation of $IgA$ deposits and a high risk of a false negative.\n-   **Fixation:** \"formalin\" is incorrect for standard DIF. The principle \"cross-linking fixatives can mask epitopes and interfere with fluorophore–antibody binding\" directly applies. Formalin is a cross-linking fixative used for routine histology and immunohistochemistry, not immunofluorescence.\n-   **Freezing:** Freezing in a \"domestic $-20^{\\circ}\\text{C}$ freezer\" is slow freezing, which leads to the ice crystal artifacts the workflow is supposed to prevent.\n-   **Staining:** Staining for \"immunoglobulin G\" ($IgG$) is incorrect. The diagnostic immunoglobulin in $DH$ is $IgA$.\n\n**Verdict:** Incorrect. This workflow is flawed in every critical step and would almost certainly yield a false-negative or uninterpretable result.\n\n**B. Re-biopsy from perilesional normal-appearing skin adjacent to a fresh lesion on an extensor surface, place tissue immediately in Michel’s transport medium if immediate freezing is not possible, avoid freezing during transport, and upon receipt embed in Optimal Cutting Temperature (OCT) compound and snap-freeze using pre-cooled isopentane in liquid nitrogen to minimize ice crystal formation; cut and stain promptly for immunoglobulin A (IgA) and complement component $3$ (C3), and store any remaining unstained sections at $-80^{\\circ}\\text{C}$ while avoiding repeated freeze–thaw cycles.**\n\n-   **Biopsy Site:** \"perilesional normal-appearing skin\" is the correct site, maximizing the chance of finding intact $IgA$ deposits.\n-   **Transport:** \"Michel’s transport medium\" is the standard of care for transporting tissue for DIF when immediate freezing is unavailable. It is a buffered, high-salt solution that preserves protein conformation without cross-linking, thus preventing proteolysis and maintaining antigenicity.\n-   **Freezing:** \"snap-freeze using pre-cooled isopentane in liquid nitrogen\" is the gold-standard method for rapid freezing. This minimizes the formation of large ice crystals, preserving tissue microarchitecture as required by the principles.\n-   **Staining:** Staining promptly for \"$IgA$\" is correct. Co-staining for complement component $3$ ($C3$) is also appropriate as it often co-localizes with $IgA$ in $DH$.\n-   **Storage:** Storing remaining sections at \"$-80^{\\circ}\\text{C}$\" and \"avoiding repeated freeze–thaw cycles\" are correct procedures for long-term preservation of antigenicity, directly addressing the flaws in the original protocol.\n\n**Verdict:** Correct. This option systematically addresses and corrects every technical flaw from the initial failed attempt, adhering perfectly to the provided first principles and representing the best practice for a DIF study in suspected $DH$.\n\n**C. Sample oral mucosa instead of skin, transport in normal saline at room temperature for $24$ hours, slow-freeze directly in the cryostat without embedding, perform staining for tissue transglutaminase antigen, and keep slides at $4^{\\circ}\\text{C}$ for $1$ month before reading.**\n\n-   **Biopsy Site:** While oral manifestations can occur, \"oral mucosa\" is not the primary or most reliable site for diagnosing $DH$; perilesional skin is standard.\n-   **Transport:** \"normal saline at room temperature for $24$ hours\" repeats the saline error and worsens it with room temperature transport, which would accelerate proteolytic degradation.\n-   **Freezing:** \"slow-freeze directly in the cryostat\" repeats the error of slow freezing, guaranteeing ice crystal artifact.\n-   **Staining:** Staining for \"tissue transglutaminase antigen\" is incorrect. The diagnostic test looks for deposited patient *antibodies* ($IgA$), not the *antigen* itself.\n-   **Storage:** Storing stained slides at \"$4^{\\circ}\\text{C}$ for $1$ month\" is poor practice, as it leads to significant fading of the fluorescent signal.\n\n**Verdict:** Incorrect. This option is flawed in its choice of site, transport, freezing, target molecule, and storage.\n\n**D. Use formalin-fixed, paraffin-embedded tissue to perform immunohistochemistry (IHC) for IgA with heat-induced epitope retrieval, incubate slides at $37^{\\circ}\\text{C}$ for $72$ hours before staining, and do not change transport media because fixatives stabilize proteins.**\n\n-   **Methodology:** This proposes switching to immunohistochemistry ($IHC$) on formalin-fixed, paraffin-embedded ($FFPE$) tissue. While technically possible, DIF on frozen tissue is the validated gold standard for $DH$ diagnosis due to its superior sensitivity and preservation of the characteristic granular pattern. Proposing a non-standard test is not the most appropriate way to troubleshoot the standard test. Furthermore, it explicitly uses a cross-linking fixative (formalin), which the principles state can be problematic.\n-   **Incubation:** Incubating slides at \"$37^{\\circ}\\text{C}$ for $72$ hours\" is an arbitrary and harmful step. It would promote antigen denaturation, violating a core principle.\n-   **Transport:** The reasoning \"do not change transport media because fixatives stabilize proteins\" is misleading. Formalin is a fixative, not a transport medium in this context, and it causes the wrong type of stabilization (cross-linking) for this immunological test.\n\n**Verdict:** Incorrect. This option proposes a suboptimal method and includes scientifically unsound procedural steps that would likely degrade the sample. It fails to correctly troubleshoot the standard DIF procedure.", "answer": "$$\\boxed{B}$$", "id": "4433734"}, {"introduction": "While pharmacologic agents control the symptoms of dermatitis herpetiformis, a strict gluten-free diet is the only therapy that addresses the underlying autoimmune pathophysiology. This exercise allows you to quantify the effect of this dietary intervention by modeling the decay of serum autoantibodies using first-order kinetics. By calculating the expected decline in IgA anti-TG2 titers over time, you can develop a deeper, quantitative understanding of the disease's response to its definitive treatment. [@problem_id:4433736]", "problem": "A patient with dermatitis herpetiformis (an autoimmune blistering disorder associated with gluten-sensitive enteropathy) has a baseline serum immunoglobulin A (IgA) anti–tissue transglutaminase 2 (TG2) titer of $100 \\ \\mathrm{U/mL}$. After initiation of a strict gluten-free diet (GFD), assume the antigen-driven production of IgA anti-TG2 becomes negligible and the decline of the circulating titer follows first-order kinetics. The effective half-life is $50$ days, defined as the time $T_{1/2}$ at which the concentration falls to one half of its value. Using the fundamental definition of first-order decay as governed by a first-order differential equation and the definition of half-life as a special time point of that decay, determine the expected IgA anti-TG2 titer after $6$ months of continuous strict GFD, taking $6$ months to be $180$ days for this calculation. Round your answer to four significant figures and express it in $\\mathrm{U/mL}$.", "solution": "The problem is first validated against the required criteria.\n\n### Step 1: Extract Givens\n- Initial IgA anti-TG2 titer: $C(0) = C_0 = 100 \\ \\mathrm{U/mL}$\n- Kinetic model: First-order decay\n- Post-GFD assumption: Antigen-driven production becomes negligible.\n- Effective half-life: $T_{1/2} = 50$ days\n- Time for calculation: $t = 180$ days (stated as equivalent to $6$ months)\n- Required output: Titer at $t=180$ days, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded. The decay of antibody titers following antigen removal (in this case, gluten in a patient with gluten-sensitive enteropathy) is a well-established immunological phenomenon, and modeling this process with first-order kinetics is a standard and appropriate approach in pharmacokinetics and immunology. The given half-life of $50$ days for an IgA subtype is biologically plausible. The problem is well-posed, providing a clear initial condition, a kinetic model, a defined parameter ($T_{1/2}$), and a specific time point for evaluation. It is self-contained, consistent, and uses objective, precise language. No flaws are identified.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\nThe decay of the circulating titer is stated to follow first-order kinetics. Let $C(t)$ represent the concentration (titer) of IgA anti-TG2 at time $t$. According to the definition of first-order kinetics, the rate of change of the concentration is directly proportional to the concentration itself. This is expressed by the following first-order linear ordinary differential equation:\n$$\n\\frac{dC(t)}{dt} = -k C(t)\n$$\nwhere $k$ is the positive first-order rate constant, and the negative sign indicates that the concentration is decreasing over time.\n\nThis differential equation can be solved by separation of variables:\n$$\n\\frac{dC}{C} = -k \\, dt\n$$\nIntegrating both sides from the initial time $t=0$ to a later time $t$:\n$$\n\\int_{C_0}^{C(t)} \\frac{1}{C'} \\, dC' = \\int_{0}^{t} -k \\, dt'\n$$\nwhere $C_0$ is the initial concentration at $t=0$. The integration yields:\n$$\n[\\ln(C')]_{C_0}^{C(t)} = [-kt']_{0}^{t}\n$$\n$$\n\\ln(C(t)) - \\ln(C_0) = -kt\n$$\n$$\n\\ln\\left(\\frac{C(t)}{C_0}\\right) = -kt\n$$\nExponentiating both sides gives the solution for $C(t)$:\n$$\nC(t) = C_0 \\exp(-kt)\n$$\nThe problem provides the half-life, $T_{1/2}$, which is defined as the time required for the concentration to fall to one-half of its initial value. We use this information to determine the rate constant $k$. At $t = T_{1/2}$, the concentration is $C(T_{1/2}) = \\frac{1}{2} C_0$. Substituting this into the general solution:\n$$\n\\frac{1}{2} C_0 = C_0 \\exp(-k T_{1/2})\n$$\nDividing by $C_0$ (which is non-zero):\n$$\n\\frac{1}{2} = \\exp(-k T_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k T_{1/2}\n$$\nUsing the property of logarithms $\\ln(1/x) = -\\ln(x)$:\n$$\n-\\ln(2) = -k T_{1/2}\n$$\nSolving for the rate constant $k$:\n$$\nk = \\frac{\\ln(2)}{T_{1/2}}\n$$\nNow we substitute this expression for $k$ back into the solution for $C(t)$:\n$$\nC(t) = C_0 \\exp\\left(-\\frac{\\ln(2)}{T_{1/2}} t\\right)\n$$\nThis equation can be rewritten in a more direct form using the properties of exponents:\n$$\nC(t) = C_0 \\left(\\exp(\\ln(2))\\right)^{-t/T_{1/2}} = C_0 \\cdot 2^{-t/T_{1/2}}\n$$\nWe are given the following values:\nInitial concentration, $C_0 = 100 \\ \\mathrm{U/mL}$\nHalf-life, $T_{1/2} = 50$ days\nTime, $t = 180$ days\n\nSubstituting these values into the equation for $C(t)$:\n$$\nC(180) = 100 \\cdot 2^{-180/50}\n$$\nFirst, we evaluate the exponent:\n$$\n\\frac{180}{50} = \\frac{18}{5} = 3.6\n$$\nSo, the equation becomes:\n$$\nC(180) = 100 \\cdot 2^{-3.6}\n$$\nNow we calculate the numerical value:\n$$\n2^{-3.6} \\approx 0.08246718...\n$$\n$$\nC(180) = 100 \\times 0.08246718... = 8.246718...\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $8$, $2$, $4$, and $6$. The fifth digit is $7$, which is $5$ or greater, so we round up the fourth significant digit.\n$$\nC(180) \\approx 8.247 \\ \\mathrm{U/mL}\n$$\nThus, the expected IgA anti-TG2 titer after $6$ months ($180$ days) is $8.247 \\ \\mathrm{U/mL}$.", "answer": "$$\\boxed{8.247}$$", "id": "4433736"}, {"introduction": "Dapsone provides rapid and effective symptomatic relief for dermatitis herpetiformis, but its use requires careful management of significant hematologic risks. This scenario presents a common and critical challenge: tailoring therapy for a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency, where the risk of oxidant-induced hemolysis is high. This practice will hone your ability to perform risk-adjusted dose calculations and develop a rational framework for using alternative agents when first-line therapy is limited. [@problem_id:4433665]", "problem": "A patient aged $32$ years with biopsy-proven dermatitis herpetiformis characterized by granular Immunoglobulin A (IgA) deposition in the dermal papillae and clinical response to dapsone presents with known glucose-6-phosphate dehydrogenase (G6PD) deficiency documented by quantitative enzymatic activity at $0.2$ of normal. In G6PD deficiency, oxidant stress from dapsone metabolites elevates the risk of hemolytic anemia and methemoglobinemia. To reduce this risk, you elect to cap the dapsone regimen at $0.5$ mg/kg/day regardless of clinical severity.\n\nThe patient’s body weight is $83.75$ kg. Compute the risk-adjusted daily dapsone dose under this cap. Express the final dose in mg and round your answer to three significant figures.\n\nSeparately, outline a rational alternative framework using sulfapyridine, noting how dosing could be structured if dapsone is contraindicated or limited by toxicity, without performing any additional calculations for sulfapyridine.", "solution": "The problem presents a clinical scenario requiring a dose calculation and a conceptual discussion of an alternative treatment. I will first validate the problem statement and then proceed to the solution.\n\n### Step 1: Extract Givens\n- Patient age: $32$ years\n- Diagnosis: Dermatitis herpetiformis, confirmed by biopsy showing granular Immunoglobulin A (IgA) deposition and clinical response to dapsone.\n- Comorbidity: Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n- G6PD enzyme activity: $0.2$ of normal.\n- Clinical constraint: The dapsone regimen is capped at $0.5$ mg/kg/day to mitigate the risk of hemolytic anemia and methemoglobinemia.\n- Patient's body weight: $83.75$ kg.\n- Task 1: Compute the risk-adjusted daily dapsone dose in mg, rounded to three significant figures.\n- Task 2: Outline a rational alternative framework using sulfapyridine.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The pathophysiology described is accurate. Dermatitis herpetiformis is an autoimmune blistering disease strongly associated with celiac disease, characterized by granular IgA deposits. Dapsone is the first-line treatment. The risk of dapsone-induced hemolysis and methemoglobinemia, and its exacerbation in G6PD-deficient individuals, is a cornerstone of clinical pharmacology. The described dose-capping strategy is a standard risk-mitigation approach.\n- **Well-Posedness**: The problem provides all necessary data for the calculation: the specific dose cap per unit of body weight and the patient's body weight. The rounding instruction is precise. The second part asks for a conceptual outline, which is a standard form of inquiry in clinical sciences. A unique and meaningful solution exists for both parts.\n- **Objectivity**: The problem is stated in clear, unbiased clinical language.\n\nThe problem does not violate any of the invalidity criteria. It is a valid, formalizable problem rooted in established medical principles.\n\n### Step 3: Verdict and Action\nThe problem is valid. I will proceed with the solution, which consists of two parts as requested.\n\n### Part 1: Dapsone Dose Calculation\n\nThe risk-adjusted daily dose is determined by applying the specified cap to the patient's body weight.\n\nLet $W$ be the patient's body weight and $D_{\\text{cap}}$ be the capped dose per kilogram per day.\nThe given values are:\n- Body weight, $W = 83.75$ kg.\n- Dose cap, $D_{\\text{cap}} = 0.5$ mg/kg/day.\n\nThe total daily dose, $D_{\\text{total}}$, is the product of the body weight and the dose cap:\n$$D_{\\text{total}} = W \\times D_{\\text{cap}}$$\nSubstituting the given values:\n$$D_{\\text{total}} = (83.75 \\, \\text{kg}) \\times (0.5 \\, \\frac{\\text{mg}}{\\text{kg} \\cdot \\text{day}})$$\n$$D_{\\text{total}} = 41.875 \\, \\frac{\\text{mg}}{\\text{day}}$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value is $41.875$. The first three significant figures are $4$, $1$, and $8$. The fourth digit is $7$, which is greater than or equal to $5$, so we round up the third digit ($8$) to $9$.\nTherefore, the rounded risk-adjusted daily dose is $41.9$ mg.\n\n### Part 2: Alternative Framework Using Sulfapyridine\n\nIf dapsone is contraindicated (e.g., due to severe G6PD deficiency) or limited by unacceptable toxicity (e.g., significant hemolysis even at a low dose), an alternative therapeutic agent is required. Sulfapyridine is a well-established second-line treatment for dermatitis herpetiformis.\n\nA rational framework for using sulfapyridine would be as follows:\n\n1.  **Rationale for Selection**: Sulfapyridine is an effective sulfonamide for controlling dermatitis herpetiformis. While generally less potent than dapsone, it does not carry the same high level of risk for oxidant-induced hemolysis and is therefore a safer option in patients with G6PD deficiency. It is considered the primary alternative when dapsone cannot be used.\n\n2.  **Dosing Structure**:\n    - **Initiation**: Treatment should begin at a low dose to assess for hypersensitivity and other immediate adverse effects. A typical starting dose is $500$ mg once or twice daily.\n    - **Titration**: The dose is gradually increased every $3$ to $7$ days based on clinical response (reduction in pruritus and new lesion formation) and patient tolerance.\n    - **Maintenance**: The dosage is titrated upwards to achieve and maintain disease control. The typical maintenance dose ranges from $1$ gram to $4$ grams per day, administered in divided doses ($2$ to $4$ times daily) to maintain stable plasma concentrations and minimize gastrointestinal side effects. The goal is to use the lowest effective dose that keeps the patient free of symptoms and new lesions.\n\n3.  **Required Monitoring**: As with other sulfonamides, sulfapyridine requires careful monitoring.\n    - **Baseline**: Before initiation, a complete blood count (CBC) with differential, renal function tests (e.g., serum creatinine), and liver function tests (e.g., ALT, AST) should be obtained.\n    - **Ongoing**: Regular monitoring of CBC is critical, especially during the first few months of therapy, to screen for potential hematologic toxicities such as agranulocytosis, aplastic anemia, or thrombocytopenia. Renal and hepatic function should also be monitored periodically. Patients should be counseled to maintain adequate hydration to prevent crystalluria.\n\nThis structured approach allows for the safe and effective use of sulfapyridine as an alternative to dapsone in managing dermatitis herpetiformis in a high-risk patient with G6PD deficiency.", "answer": "$$\\boxed{41.9}$$", "id": "4433665"}]}